Advertisement

Fertility Preservation and Pregnancy After Breast Cancer

  • Matteo Lambertini
  • Fedro A. PeccatoriEmail author
Chapter
  • 68 Downloads

Abstract

Fertility- and pregnancy-related issues are considered one of the priority areas of concerns for young breast cancer patients. Major international guidelines highlight the importance of counseling all cancer patients diagnosed during their reproductive years on the possible risk of treatment-induced premature ovarian insufficiency and infertility and then informing interested patients about the different available options for fertility preservation. Nowadays, oncofertility counseling should be considered standard of care in all newly diagnosed young cancer patients. However, despite the development of specific programs to support clinicians in discussing concerns related to fertility and pregnancy with young patients, there are still several barriers on this regard and not all patients are adequately informed, thus limiting the access to fertility preservation procedures and reducing the chance of future pregnancies. Hence, the percentage of patients who achieve a pregnancy after the end of treatment remains low, especially among breast cancer survivors.

The aim of the present chapter is to highlight the risk of treatment-induced premature ovarian insufficiency and infertility in young women with breast cancer, to review the available data on the different fertility preservation options in these patients, and to discuss the safety issues of pregnancy in breast cancer survivors.

Keywords

Breast cancer Premature ovarian insufficiency Fertility preservation Embryo and oocyte cryopreservation Ovarian tissue cryopreservation Gonadotropin-releasing hormone analogs Pregnancy 

References

  1. 1.
    Paluch-Shimon S, Pagani O, Partridge AH, Abulkhair O, Cardoso M-J, Dent RA, et al. ESO-ESMO 3rd international consensus guidelines for breast cancer in young women (BCY3). Breast. 2017;35:203–17.PubMedCrossRefPubMedCentralGoogle Scholar
  2. 2.
    Lambertini M, Goldrat O, Clatot F, Demeestere I, Awada A. Controversies about fertility and pregnancy issues in young breast cancer patients: current state of the art. Curr Opin Oncol. 2017;29(4):243–52.PubMedCrossRefPubMedCentralGoogle Scholar
  3. 3.
    Ruddy KJ, Gelber SI, Tamimi RM, Ginsburg ES, Schapira L, Come SE, et al. Prospective study of fertility concerns and preservation strategies in young women with breast cancer. J Clin Oncol. 2014;32(11):1151–6.PubMedPubMedCentralCrossRefGoogle Scholar
  4. 4.
    Loren AW, Mangu PB, Beck LN, Brennan L, Magdalinski AJ, Partridge AH, et al. Fertility preservation for patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2013;31(19):2500–10.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Peccatori FA, Azim HA Jr, Orecchia R, Hoekstra HJ, Pavlidis N, Kesic V, et al. Cancer, pregnancy and fertility: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):vi160–70.PubMedCrossRefPubMedCentralGoogle Scholar
  6. 6.
    Lambertini M, Anserini P, Levaggi A, Poggio F, Del Mastro L. Fertility counseling of young breast cancer patients. J Thorac Dis. 2013;5(Suppl 1):S68–80.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Woodruff TK, Smith K, Gradishar W. Oncologists’ role in patient fertility care: a call to action. JAMA Oncol. 2016;2(2):171–2.PubMedPubMedCentralCrossRefGoogle Scholar
  8. 8.
    Quinn GP, Vadaparampil ST, Gwede CK, Reinecke JD, Mason TM, Silva C. Developing a referral system for fertility preservation among patients with newly diagnosed cancer. J Natl Compr Cancer Netw. 2011;9(11):1219–25.CrossRefGoogle Scholar
  9. 9.
    Kelvin JF, Reinecke J. Institutional approaches to implementing fertility preservation for cancer patients. Adv Exp Med Biol. 2012;732:165–73.PubMedCrossRefPubMedCentralGoogle Scholar
  10. 10.
    Reinecke JD, Kelvin JF, Arvey SR, Quinn GP, Levine J, Beck LN, et al. Implementing a systematic approach to meeting patients’ cancer and fertility needs: a review of the fertile Hope centers of excellence program. J Oncol Pract. 2012;8(5):303–8.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Partridge AH, Ruddy KJ, Kennedy J, Winer EP. Model program to improve care for a unique cancer population: young women with breast cancer. J Oncol Pract. 2012;8(5):e105–10.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Clayman ML, Harper MM, Quinn GP, Reinecke J, Shah S. Oncofertility resources at NCI-designated comprehensive cancer centers. J Natl Compr Cancer Netw. 2013;11(12):1504–9.CrossRefGoogle Scholar
  13. 13.
    Kelvin JF, Thom B, Benedict C, Carter J, Corcoran S, Dickler MN, et al. Cancer and fertility program improves patient satisfaction with information received. J Clin Oncol. 2016;34(15):1780–6.PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    Biglia N, Torrisi R, D’Alonzo M, Codacci Pisanelli G, Rota S, Peccatori FA. Attitudes on fertility issues in breast cancer patients: an Italian survey. Gynecol Endocrinol. 2015;31(6):458–64.PubMedCrossRefPubMedCentralGoogle Scholar
  15. 15.
    Lambertini M, Di Maio M, Pagani O, Curigliano G, Poggio F, Del Mastro L, et al. The BCY3/BCC 2017 survey on physicians’ knowledge, attitudes and practice towards fertility and pregnancy-related issues in young breast cancer patients. Breast. 2018;42:41–9.PubMedCrossRefPubMedCentralGoogle Scholar
  16. 16.
    Stensheim H, Cvancarova M, Møller B, Fosså SD. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129(5):1225–36.PubMedCrossRefPubMedCentralGoogle Scholar
  17. 17.
    Lee SJ, Schover LR, Partridge AH, Patrizio P, Wallace WH, Hagerty K, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol. 2006;24(18):2917–31.PubMedCrossRefPubMedCentralGoogle Scholar
  18. 18.
    Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril. 2008;90(5):1635–9.PubMedCrossRefPubMedCentralGoogle Scholar
  19. 19.
    Lambertini M, Ceppi M, Cognetti F, Cavazzini G, De Laurentiis M, De Placido S, et al. Dose-dense adjuvant chemotherapy in premenopausal breast cancer patients: a pooled analysis of the MIG1 and GIM2 phase III studies. Eur J Cancer. 2017;71:34–42.PubMedCrossRefPubMedCentralGoogle Scholar
  20. 20.
    Ganz PA, Land SR, Geyer CE Jr, Cecchini RS, Costantino JP, Pajon ER, et al. Menstrual history and quality-of-life outcomes in women with node-positive breast cancer treated with adjuvant therapy on the NSABP B-30 trial. J Clin Oncol. 2011;29(9):1110–6.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Bedoschi G, Navarro PA, Oktay K. Chemotherapy-induced damage to ovary: mechanisms and clinical impact. Future Oncol. 2016;12(20):2333–44.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Codacci-Pisanelli G, Del Pup L, Del Grande M, Peccatori FA. Mechanisms of chemotherapy-induced ovarian damage in breast cancer patients. Crit Rev Oncol Hematol. 2017;113:90–6.PubMedCrossRefPubMedCentralGoogle Scholar
  23. 23.
    Practice Committee of the American Society for Reproductive Medicine. Fertility preservation in patients undergoing gonadotoxic therapy or gonadectomy: a committee opinion. Fertil Steril. 2013;100(5):1214–23.CrossRefGoogle Scholar
  24. 24.
    European IVF-Monitoring Consortium (EIM) for the European Society of Human Reproduction and Embryology (ESHRE), Calhaz-Jorge C, de Geyter C, Kupka MS, de Mouzon J, Erb K, et al. Assisted reproductive technology in Europe, 2012: results generated from European registers by ESHRE. Hum Reprod. 2016;31(8):1638–52.CrossRefGoogle Scholar
  25. 25.
    Meirow D, Schiff E. Appraisal of chemotherapy effects on reproductive outcome according to animal studies and clinical data. J Natl Cancer Inst Monogr. 2005;2005(34):21–5.CrossRefGoogle Scholar
  26. 26.
    Lambertini M, Pescio MC, Viglietti G, Goldrat O, Del Mastro L, Anserini P, Demeestere I. Methods of controlled ovarian stimulation for embryo/oocyte cryopreservation in breast cancer patients. Expert Rev Qual Life Cancer Care. 2017;2(1):47–59.CrossRefGoogle Scholar
  27. 27.
    Oktay K, Hourvitz A, Sahin G, Oktem O, Safro B, Cil A, et al. Letrozole reduces estrogen and gonadotropin exposure in women with breast cancer undergoing ovarian stimulation before chemotherapy. J Clin Endocrinol Metab. 2006;91(10):3885–90.PubMedCrossRefPubMedCentralGoogle Scholar
  28. 28.
    Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol. 2008;26(16):2630–5.PubMedCrossRefPubMedCentralGoogle Scholar
  29. 29.
    Oktay K, Buyuk E, Davis O, Yermakova I, Veeck L, Rosenwaks Z. Fertility preservation in breast cancer patients: IVF and embryo cryopreservation after ovarian stimulation with tamoxifen. Hum Reprod. 2003;18(1):90–5.PubMedCrossRefPubMedCentralGoogle Scholar
  30. 30.
    Meirow D, Raanani H, Maman E, Paluch-Shimon S, Shapira M, Cohen Y, et al. Tamoxifen co-administration during controlled ovarian hyperstimulation for in vitro fertilization in breast cancer patients increases the safety of fertility-preservation treatment strategies. Fertil Steril. 2014;102(2):488–495.e3.PubMedCrossRefPubMedCentralGoogle Scholar
  31. 31.
    Oktay K, Turan V, Bedoschi G, Pacheco FS, Moy F. Fertility preservation success subsequent to concurrent aromatase inhibitor treatment and ovarian stimulation in women with breast Cancer. J Clin Oncol. 2015;33(22):2424–9.PubMedPubMedCentralCrossRefGoogle Scholar
  32. 32.
    Revelli A, Porcu E, Levi Setti PE, Delle Piane L, Merlo DF, Anserini P. Is letrozole needed for controlled ovarian stimulation in patients with estrogen receptor-positive breast cancer? Gynecol Endocrinol. 2013;29(11):993–6.PubMedCrossRefPubMedCentralGoogle Scholar
  33. 33.
    Pereira N, Hancock K, Cordeiro CN, Lekovich JP, Schattman GL, Rosenwaks Z. Comparison of ovarian stimulation response in patients with breast cancer undergoing ovarian stimulation with letrozole and gonadotropins to patients undergoing ovarian stimulation with gonadotropins alone for elective cryopreservation of oocytes†. Gynecol Endocrinol. 2016;32(10):823–6.PubMedCrossRefPubMedCentralGoogle Scholar
  34. 34.
    Kim J, Turan V, Oktay K. Long-term safety of Letrozole and gonadotropin stimulation for fertility preservation in women with breast Cancer. J Clin Endocrinol Metab. 2016;101(4):1364–71.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Balkenende EME, Dahhan T, Linn SC, Jager NGL, Beijnen JH, Goddijn M. A prospective case series of women with estrogen receptor-positive breast cancer: levels of tamoxifen metabolites in controlled ovarian stimulation with high-dose tamoxifen. Hum Reprod. 2013;28(4):953–9.PubMedCrossRefPubMedCentralGoogle Scholar
  36. 36.
    Cakmak H, Katz A, Cedars MI, Rosen MP. Effective method for emergency fertility preservation: random-start controlled ovarian stimulation. Fertil Steril. 2013;100(6):1673–80.PubMedCrossRefPubMedCentralGoogle Scholar
  37. 37.
    Kuang Y, Chen Q, Hong Q, Lyu Q, Ai A, Fu Y, et al. Double stimulations during the follicular and luteal phases of poor responders in IVF/ICSI programmes (Shanghai protocol). Reprod Biomed Online. 2014;29(6):684–91.PubMedCrossRefPubMedCentralGoogle Scholar
  38. 38.
    Shalom-Paz E, Almog B, Shehata F, Huang J, Holzer H, Chian R-C, et al. Fertility preservation for breast-cancer patients using IVM followed by oocyte or embryo vitrification. Reprod Biomed Online. 2010;21(4):566–71.PubMedCrossRefPubMedCentralGoogle Scholar
  39. 39.
    Chian R-C, Uzelac PS, Nargund G. In vitro maturation of human immature oocytes for fertility preservation. Fertil Steril. 2013;99(5):1173–81.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Walls ML, Hunter T, Ryan JP, Keelan JA, Nathan E, Hart RJ. In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes. Hum Reprod. 2015;30(1):88–96.PubMedCrossRefPubMedCentralGoogle Scholar
  41. 41.
    Rosendahl M, Greve T, Andersen CY. The safety of transplanting cryopreserved ovarian tissue in cancer patients: a review of the literature. J Assist Reprod Genet. 2013;30(1):11–24.PubMedCrossRefPubMedCentralGoogle Scholar
  42. 42.
    Lambertini M, Del Mastro L, Pescio MC, Andersen CY, Azim HA, Peccatori FA, et al. Cancer and fertility preservation: international recommendations from an expert meeting. BMC Med. 2016;14(1):1.PubMedPubMedCentralCrossRefGoogle Scholar
  43. 43.
    Kim SS, Lee WS, Chung MK, Lee HC, Lee HH, Hill D. Long-term ovarian function and fertility after heterotopic autotransplantation of cryobanked human ovarian tissue: 8-year experience in cancer patients. Fertil Steril. 2009;91(6):2349–54.PubMedCrossRefPubMedCentralGoogle Scholar
  44. 44.
    Andersen CY, Silber SJ, Bergholdt SH, Berghold SH, Jorgensen JS, Ernst E. Long-term duration of function of ovarian tissue transplants: case reports. Reprod Biomed Online. 2012;25(2):128–32.PubMedCrossRefPubMedCentralGoogle Scholar
  45. 45.
    Donnez J, Dolmans M-M, Pellicer A, Diaz-Garcia C, Ernst E, Macklon KT, et al. Fertility preservation for age-related fertility decline. Lancet. 2015;385(9967):506–7.PubMedCrossRefPubMedCentralGoogle Scholar
  46. 46.
    Andersen CY. Success and challenges in fertility preservation after ovarian tissue grafting. Lancet. 2015;385(9981):1947–8.PubMedCrossRefPubMedCentralGoogle Scholar
  47. 47.
    Van der Ven H, Liebenthron J, Beckmann M, Toth B, Korell M, Krüssel J, et al. Ninety-five orthotopic transplantations in 74 women of ovarian tissue after cytotoxic treatment in a fertility preservation network: tissue activity, pregnancy and delivery rates. Hum Reprod. 2016;31(9):2031–41.PubMedCrossRefPubMedCentralGoogle Scholar
  48. 48.
    Jensen AK, Macklon KT, Fedder J, Ernst E, Humaidan P, Andersen CY. 86 successful births and 9 ongoing pregnancies worldwide in women transplanted with frozen-thawed ovarian tissue: focus on birth and perinatal outcome in 40 of these children. J Assist Reprod Genet. 2017;34(3):325–36.PubMedCrossRefPubMedCentralGoogle Scholar
  49. 49.
    Lambertini M, Ginsburg ES, Partridge AH. Update on fertility preservation in young women undergoing breast cancer and ovarian cancer therapy. Curr Opin Obstet Gynecol. 2015;27(1):98–107.PubMedCrossRefPubMedCentralGoogle Scholar
  50. 50.
    Turner NH, Partridge A, Sanna G, Di Leo A, Biganzoli L. Utility of gonadotropin-releasing hormone agonists for fertility preservation in young breast cancer patients: the benefit remains uncertain. Ann Oncol. 2013;24(9):2224–35.PubMedCrossRefPubMedCentralGoogle Scholar
  51. 51.
    Del Mastro L, Lambertini M. Temporary ovarian suppression with gonadotropin-releasing hormone agonist during chemotherapy for fertility preservation: toward the end of the debate? Oncologist. 2015;20(11):1233–5.PubMedPubMedCentralCrossRefGoogle Scholar
  52. 52.
    Lambertini M, Peccatori FA, Moore HCF, Del Mastro L. Reply to the letter to the editor “can ovarian suppression with gonadotropin releasing hormone analogs (GnRHa) preserve fertility in cancer patients?” by Rodriguez-Wallberg et al. Ann Oncol. 2016;27(3):548–9.PubMedCrossRefPubMedCentralGoogle Scholar
  53. 53.
    Lambertini M, Falcone T, Unger JM, Phillips K-A, Del Mastro L, Moore HCF. Debated role of ovarian protection with gonadotropin-releasing hormone agonists during chemotherapy for preservation of ovarian function and fertility in women with Cancer. J Clin Oncol. 2017;35(7):804–5.PubMedCrossRefPubMedCentralGoogle Scholar
  54. 54.
    Lambertini M, Poggio F, Vaglica M, Blondeaux E, Del Mastro L. News on the medical treatment of young women with early-stage HER2-negative breast cancer. Expert Opin Pharmacother. 2016;17(12):1643–55.PubMedCrossRefPubMedCentralGoogle Scholar
  55. 55.
    Lambertini M, Boni L, Michelotti A, Gamucci T, Scotto T, Gori S, et al. Ovarian suppression with Triptorelin during adjuvant breast Cancer chemotherapy and long-term ovarian function, pregnancies, and disease-free survival: a randomized clinical trial. JAMA. 2015;314(24):2632–40.PubMedCrossRefPubMedCentralGoogle Scholar
  56. 56.
    Leonard RCF, Adamson DJA, Bertelli G, Mansi J, Yellowlees A, Dunlop J, et al. GnRH agonist for protection against ovarian toxicity during chemotherapy for early breast cancer: the Anglo Celtic group OPTION trial. Ann Oncol. 2017;28(8):1811–6.PubMedCrossRefPubMedCentralGoogle Scholar
  57. 57.
    Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Moseley A, et al. Final analysis of the prevention of early menopause study (POEMS)/SWOG intergroup S0230. J Natl Cancer Inst. 2019;111(2):210–3. Epub ahead of printPubMedCrossRefPubMedCentralGoogle Scholar
  58. 58.
    Lambertini M, Ceppi M, Poggio F, Peccatori FA, Azim HA, Ugolini D, et al. Ovarian suppression using luteinizing hormone-releasing hormone agonists during chemotherapy to preserve ovarian function and fertility of breast cancer patients: a meta-analysis of randomized studies. Ann Oncol. 2015;26(12):2408–19.PubMedCrossRefPubMedCentralGoogle Scholar
  59. 59.
    Lambertini M, Cinquini M, Moschetti I, Peccatori FA, Anserini P, Valenzano Menada M, et al. Temporary ovarian suppression during chemotherapy to preserve ovarian function and fertility in breast cancer patients: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology. Eur J Cancer. 2017;71:25–33.PubMedCrossRefPubMedCentralGoogle Scholar
  60. 60.
    Oktay K, Harvey BE, Partridge AH, Quinn GP, Reinecke J, Taylor HS, et al. Fertility preservation in patients with Cancer: ASCO clinical practice guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2018;36(19):1994–2001.CrossRefGoogle Scholar
  61. 61.
    Letourneau JM, Smith JF, Ebbel EE, Craig A, Katz PP, Cedars MI, et al. Racial, socioeconomic, and demographic disparities in access to fertility preservation in young women diagnosed with cancer. Cancer. 2012;118(18):4579–88.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Moore HCF, Unger JM, Phillips K-A, Boyle F, Hitre E, Porter D, et al. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. N Engl J Med. 2015;372(10):923–32.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Hartman EK, Eslick GD. The prognosis of women diagnosed with breast cancer before, during and after pregnancy: a meta-analysis. Breast Cancer Res Treat. 2016;160(2):347–60.PubMedCrossRefPubMedCentralGoogle Scholar
  64. 64.
    Azim HA Jr, Kroman N, Paesmans M, Gelber S, Rotmensz N, Ameye L, et al. Prognostic impact of pregnancy after breast cancer according to estrogen receptor status: a multicenter retrospective study. J Clin Oncol. 2013;31(1):73–9.PubMedCrossRefPubMedCentralGoogle Scholar
  65. 65.
    Lambertini M, Kroman N, Ameye L, Cordoba O, Pinto A, Benedetti G, et al. Long-term safety of pregnancy following breast cancer according to estrogen receptor status. J Natl Cancer Inst. 2018;110(4):426–9.PubMedCrossRefPubMedCentralGoogle Scholar
  66. 66.
    Pagani O, Ruggeri M, Manunta S, Saunders C, Peccatori F, Cardoso F, et al. Pregnancy after breast cancer: are young patients willing to participate in clinical studies? Breast. 2015;24(3):201–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Luke B, Brown MB, Missmer SA, Spector LG, Leach RE, Williams M, et al. Assisted reproductive technology use and outcomes among women with a history of cancer. Hum Reprod. 2016;31(1):183–9.PubMedCrossRefGoogle Scholar
  68. 68.
    Lambertini M, Anserini P, Fontana V, Poggio F, Iacono G, Abate A, et al. The PREgnancy and FERtility (PREFER) study: an Italian multicenter prospective cohort study on fertility preservation and pregnancy issues in young breast cancer patients. BMC Cancer. 2017;17(1):346.PubMedPubMedCentralCrossRefGoogle Scholar
  69. 69.
    Lambertini M, Fontana V, Massarotti C, Poggio F, Dellepiane C, Iacono G, et al. Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: results of the pilot phase of the PREgnancy and FERtility (PREFER) study. Breast. 2018;41:51–6.PubMedCrossRefPubMedCentralGoogle Scholar
  70. 70.
    Cohen L, Hamer J, Helwig C, Fergus K, Kiss A, Mandel R, et al. Formal evaluation of PYNK: breast cancer program for young women-the patient perspective. Curr Oncol. 2016;23(2):e102–8.PubMedPubMedCentralCrossRefGoogle Scholar
  71. 71.
    Villarreal-Garza C, Platas A, Martinez-Cannon BA, Bargalló-Rocha E, Aguilar-González CN, Ortega-Leonard V, et al. Information needs and internet use of breast cancer survivors in Mexico. Breast J. 2017;23(3):373–5.PubMedCrossRefPubMedCentralGoogle Scholar
  72. 72.
    Lambertini M, Goldrat O, Toss A, Azim HA, Peccatori FA, Ignatiadis M, et al. Fertility and pregnancy issues in BRCA-mutated breast cancer patients. Cancer Treat Rev. 2017;59:61–70.PubMedCrossRefPubMedCentralGoogle Scholar
  73. 73.
    Peccatori FA, Mangili G, Bergamini A, Filippi F, Martinelli F, Ferrari F, et al. Fertility preservation in women harboring deleterious BRCA mutations: ready for prime time? Hum Reprod. 2018;33(2):181–7.PubMedCrossRefPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Medical Oncology, Clinica di Oncologia Medica, Policlinico San Martino-ISTUniversity of GenovaGenoaItaly
  2. 2.Fertility and Procreation Unit, Division of Gynecologic OncologyEuropean Institute of OncologyMilanItaly

Personalised recommendations